Central Asian Research Index

Eurasian Journal of Applied Biotechnology, 2026, № 2, с. 65-72

Influence of Treg-cell subpopulations on HLA-E expression by chronic myeloid leukemia and Burkitt's B-cell lymphoma cells

S.A. Kan, A.V. Lushova, R. Tleulieva, N. Abdolla, A.M. Tolendiyeva, Yu.V. Perfilyeva, Ye.O. Ostapchuk

Аннотация · Abstract

Modern research in the field of cancer immunology traditionally identifies T regulatory (Treg) cells as key suppressors of the antitumor immune response due to their direct inhibitory effects on effector populations, such as natural killer (NK) cells and cytotoxic T lymphocytes. However, the direct influence of Treg cells on the biological and immunosuppressive properties of the tumor cells themselves remains insufficiently understood. Hematologic malignancies, including chronic myeloid leukemia and Burkitt’s lymphoma, are hematopoietic neoplasms associated with a highly unfavorable prognosis during progression, largely driven by the tumor's ability to establish an immune-privileged microenvironment. In this study, we investigated the effect of natural (nTreg) and induced (iTreg) regulatory T cells on the expression of immunosuppressive molecules by chronic myeloid leukemia (K562) and Burkitt's B-cell lymphoma (Raji) cell lines in vitro. K562 and Raji cells were cultured either in direct contact with Treg cell subpopulations or in their culture supernatants, followed by flow cytometric analysis of immunosuppressive marker expression. We demonstrated that direct cell-to-cell contact with both nTreg and iTreg cells leads to a statistically significant upregulation of HLA-E expression on the surface of both investigated cell lines. These findings indicate that regulatory T cells are capable of modifying the tumor immunophenotype, thereby enhancing the capacity for immune evasion. Consequently, the results of this study expand current understanding of the role of Treg cells in the progression of hematologic malignancies and emphasize the necessity of considering their direct impact on tumor cells when developing novel immunotherapeutic strategies.

Сведения · Details